ACTN4 and cervical cancer: For a preliminary determination of the sensitivity and specificity of ACTN4 as a cervical (pre)cancer biomarker, we extended our sample pool with 10 CVF samples from the previous cohort [63], 14 CIN III or cervical cancer samples from a Berlin cohort (see Table 1) and five samples from an African cohort, three of which were from women infected with HIV-1 [64] (Table 1).